We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ELOX market cap is 2.17M. The company's latest EPS is USD -11.4733 and P/E is -0.06.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -47.57M | -50.56M | -33.46M | -66.02M | -34.42M |
| Net Income | -47.19M | -50.87M | -34.58M | -66.73M | -36.07M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 50.72M | 58.95M | 26.48M | 45.14M | 21.12M |
| Total Liabilities | 7.81M | 22.73M | 16.25M | 22.76M | 31.78M |
| Total Equity | 42.91M | 36.21M | 10.23M | 22.38M | -10.66M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.37M | -39.39M | -28.17M | -35M | -31.85M |
| Investing | -317k | -33.52M | 33.79M | 2.06M | -66k |
| Financing | 56.18M | 46.8M | -3.44M | 50.79M | 8.81M |
| Market Cap | 2.17M |
| Price to Earnings Ratio | -0.06 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.11 |
| Price to Book Ratio | -0.2 |
| Dividend Yield | - |
| Shares Outstanding | 3.14M |
| Average Volume (1 week) | 4.19k |
| Average Volume (1 Month) | 2.87k |
| 52 Week Change | -80.35% |
| 52 Week High | 3.51 |
| 52 Week Low | 0.40 |
| Spread (Intraday) | 0.49 (44.55%) |
| Company Name | Eloxx Pharmaceuticals Inc (PK) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.eloxxpharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
